Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.46 |
| ▸ | CHUK | O15111 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 7/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | FES | P07332 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166243 | 0.80 | GRM6 (0.62) | MAPK1GRM6MEN1KMT2ATDP1 | |
| SCHEMBL5167071 | 0.79 | ESR1 (0.42) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5454349 | 0.76 | ESR1 (0.44) | IKBKBLIMK1ESR1MAPK1 | |
| SCHEMBL6135345 | 0.73 | GRM2 (0.42) | IKBKBESR1MAP4K4MEN1JAK2 | |
| SCHEMBL12562776 | 0.73 | ESR1 (0.44) | LIMK1ESR1MAP4K4BCKDK | |
| SCHEMBL29765316 | 0.72 | IKBKB (0.44) | IKBKBLIMK1ESR1TDP1LIMK2 | |
| SCHEMBL2688919 | 0.71 | LIMK1 (0.62) | IKBKBLIMK1MAPK1MEN1KMT2A | |
| SCHEMBL18470284 | 0.70 | ESR1 (0.43) | LIMK1ESR1MAP4K4 | |
| SCHEMBL3385279 | 0.70 | ALDH1A1 (0.52) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16872439 | 0.67 | ESR1 (0.40) | LIMK1ESR1MAP4K4PIM3BCKDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-7300952-B2 | NF-κb inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| EP-1532135-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| US-20060058371-A1 | Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | claimed |
| EP-1532135-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | claimed |
| EP-1532135-A1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| WO-2003104219-A1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-7300952-B2 | NF-κb inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1532135-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060058371-A1 | Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1532135-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1532135-A1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2003104219-A1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058371-A1 | Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease | NFKBIA, IKBKG, RELA | IKBKB 4/4885CHUK 5/4885CYP1A2 3597/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | IKBKB 1034/4885CHUK 725/4885CYP1A2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.